Replimune Group (NASDAQ:REPL) Trading 4.4% Higher - Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price shot up 4.4% during trading on Monday . The stock traded as high as $9.90 and last traded at $9.81. 654,968 shares traded hands during trading, a decline of 24% from the average session volume of 866,926 shares. The stock had previously closed at $9.40.

Analysts Set New Price Targets

Several research firms have commented on REPL. Piper Sandler raised their target price on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, June 2nd. Cantor Fitzgerald assumed coverage on shares of Replimune Group in a research note on Friday, June 20th. They issued an "overweight" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Replimune Group in a research note on Thursday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $20.83.

Replimune Group Stock Performance

The firm's fifty day simple moving average is $9.06 and its 200 day simple moving average is $10.53. The company has a market capitalization of $743.92 million, a price-to-earnings ratio of -3.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.25) EPS. On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, CAO Andrew Schwendenman sold 3,287 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the sale, the chief accounting officer directly owned 68,284 shares in the company, valued at approximately $549,686.20. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the sale, the director owned 1,405,071 shares of the company's stock, valued at approximately $11,324,872.26. This represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,907 shares of company stock valued at $603,655. Company insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

Several institutional investors have recently made changes to their positions in REPL. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares during the period. US Bancorp DE raised its position in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after purchasing an additional 3,921 shares during the period. Tower Research Capital LLC TRC increased its position in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd increased its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock valued at $111,000 after buying an additional 5,876 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.